Merck & Co., Inc. 2024 Q2 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Merck & Co., Inc. operates through two primary segments: Pharmaceutical (human health) and Animal Health. The company continues to drive growth through its oncology franchise, led by Keytruda, while managing patent expirations in its diabetes portfolio and navigating global pricing pressures.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Sales | $16.11 billion | $15.04 billion | $31.89 billion | $29.52 billion |
| Net Income (Attributable to Merck) | $5.46 billion | ($5.98 billion) | $10.22 billion | ($3.15 billion) |
| Diluted EPS | $2.14 | ($2.35) | $4.02 | ($1.24) |
| Operating Cash Flow (6M) | $8.73 billion (vs. $5.04 billion in 6M 2023) | |||
| Free Cash Flow (6M) | ~$7.08 billion (Operating Cash Flow less $1.65B CapEx) | |||
| Long-Term Debt | $34.72 billion (as of June 30, 2024) | |||
| Cash & Equivalents | $11.30 billion (as of June 30, 2024) | |||
| Gross Margin | 76.8% | 73.2% | 77.2% (6M) | 73.1% (6M) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 7% year-over-year in Q2 2024 (11% excluding foreign exchange). Growth was driven by the oncology franchise (Keytruda up 16%) and vaccines (Gardasil/Gardasil 9 up 1%), partially offset by declines in diabetes (Januvia/Janumet down 27%) and virology (Lagevrio down 46%).
- Profitability Surge: The company reported a significant turnaround from a net loss in Q2 2023 to a net income of $5.46 billion in Q2 2024. The prior year loss was heavily impacted by a $10.2 billion R&D charge for the Prometheus Biosciences acquisition.
- R&D Expenses: R&D expenses dropped 74% to $3.5 billion in Q2 2024 compared to $13.3 billion in Q2 2023, primarily due to the absence of the large Prometheus acquisition charge in the current period. A $656 million charge for the Harpoon Therapeutics acquisition was recorded in the first six months of 2024.
- Restructuring: The company initiated a new 2024 Restructuring Program with estimated cumulative costs of $4.0 billion, recording $177 million in pretax costs in Q2 2024.
Guidance, Outlook, and Risks
- Business Development: In July 2024, Merck acquired the aqua business of Elanco for ~$1.3 billion and Eyebiotech for an upfront $1.3 billion. The Eyebiotech deal includes a projected $1.3 billion R&D charge in Q3 2024.
- Pricing and Policy Risks: The company faces ongoing pricing pressure from the Inflation Reduction Act (IRA), specifically regarding Januvia, which is subject to government price-setting starting January 2026. The American Rescue Plan Act also eliminated the Medicaid rebate cap in 2024, impacting Januvia/Janumet margins.
- Patent Expirations: Januvia and Janumet face generic competition in Europe and Asia, with U.S. exclusivity expected to last until May/July 2026 due to salt/polymorph patents. Bridion patent exclusivity expired in the EU (July 2023) and Japan (January 2024), leading to sales declines.
- Legal Proceedings: Significant litigation includes product liability suits regarding Dr. Scholl's foot powder (talc) and Gardasil vaccines. A DOJ investigation regarding price reporting for Steglatro and Januvia is ongoing. Patent disputes continue regarding Keytruda (vs. Johns Hopkins) and Januvia (vs. generic manufacturers).
- Capital Allocation: The company maintains a $3.3 billion remaining share repurchase authorization and paid $3.9 billion in dividends during the first six months of 2024.
Investor Verification Checklist
- Keytruda Growth Sustainability: Verify the durability of Keytruda's 16% growth rate and the impact of new indications (e.g., cervical cancer, endometrial carcinoma) on future revenue.
- Januvia/Janumet Decline: Assess the magnitude of sales erosion in the diabetes franchise due to the Medicaid rebate cap removal and IRA negotiations.
- Acquisition Integration: Monitor the financial impact of the July 2024 acquisitions (Elanco, Eyebiotech) and the timing of the associated R&D charges.
- Legal Exposure: Review updates on the Dr. Scholl's talc litigation and the DOJ investigation into Medicaid rebate reporting.
- Restructuring Execution: Track the progress of the $4.0 billion restructuring program and the realization of the projected $750 million in annual cost savings by 2031.